ZLDPF - GLP-1 Drug Development Market Pile-Up Continues
2024-05-20 08:20:00 ET
Summary
- The mean weight loss in a Phase 1b trial of the GLP/GIP against CT-388 (once-a-week injection for 24 weeks) has just read out at 18.8%, with (apparently) no safety signals.
- Amgen sort-of-announced positive results on its candidate, MariTide.
- Boehringer's partnership with Zealand (of Denmark) on another peptide drug, survodutide, reported strong results in one of its multiple concurrent clinical trials.
I wrote back in February about the pileup in GLP-1 drug development, and even that post didn't get to all the things going on in this area. There's been even more news recently, so I thought that a quick update might be a good idea....
GLP-1 Drug Development Market Pile-Up Continues